Immunovia, founded in 2007, has developed a technology for analyzing the massive information contained in the blood and transferring it to clinically useful tools to diagnose complex diseases significantly earlier and more accurately than preconsciously possible.
The company has developed IMMray ™ that can diagnose cancer of the pancreas to predict the course of disease and follow the cancer response to treatment. The technology can also be used to identify biomarkers. Immunova's technology is not only designed for cancerous diseases, but also for autoimmune diseases. It is completely superior to conventional proteomics, which are slow, have low sensitivity.